Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 20 de 44
Filter
1.
J Inherit Metab Dis ; 44(3): 521-533, 2021 05.
Article in English | MEDLINE | ID: mdl-33368379

ABSTRACT

Glycogen storage disorder type III (GSDIII) is a rare inborn error of metabolism due to loss of glycogen debranching enzyme activity, causing inability to fully mobilize glycogen stores and its consequent accumulation in various tissues, notably liver, cardiac and skeletal muscle. In the pediatric population, it classically presents as hepatomegaly with or without ketotic hypoglycemia and failure to thrive. In the adult population, it should also be considered in the differential diagnosis of left ventricular hypertrophy or hypertrophic cardiomyopathy, myopathy, exercise intolerance, as well as liver cirrhosis or fibrosis with subsequent liver failure. In this review article, we first present an overview of the biochemical and clinical aspects of GSDIII. We then focus on the recent findings regarding cardiac and neuromuscular impairment associated with the disease. We review new insights into the pathophysiology and clinical picture of this disorder, including symptomatology, imaging and electrophysiology. Finally, we discuss current and upcoming treatment strategies such as gene therapy aimed at the replacement of the malfunctioning enzyme to provide a stable and long-term therapeutic option for this debilitating disease.


Subject(s)
Genetic Therapy/methods , Glycogen Storage Disease Type III/therapy , Muscle, Skeletal/physiopathology , Adult , Animals , Child , Disease Models, Animal , Glycogen Storage Disease Type III/metabolism , Glycogen Storage Disease Type III/physiopathology , Hepatomegaly/metabolism , Humans , Hypoglycemia/metabolism , Liver/metabolism , Muscle, Skeletal/metabolism , Muscular Diseases/metabolism
2.
Muscle Nerve ; 60(1): 72-79, 2019 07.
Article in English | MEDLINE | ID: mdl-30972778

ABSTRACT

INTRODUCTION: The main objective of this study was to describe muscle involvement on whole-body magnetic resonance imaging scans in adults at different stages of glycogen-storage disease type III (GSDIII). METHODS: Fifteen patients, 16-59 years of age, were examined on a 3-T system. The examinations consisted of coronal and axial T1-weighted images or fat images with a Dixon technique, and were scored for 47 muscles using Mercuri's classification. Muscle changes consisted of internal bright signals of fatty replacement. RESULTS: Distribution across muscles showed predominant signal alteration in the lower limbs and postural muscles. This finding is consistent with the overall clinical presentation of GSDIII and the results of heatmap scores. Review of the MRI scans provided new information regarding recurrent muscle changes, particularly in the soleus, gastrocnemius medial head, and thoracic extensor muscles. DISCUSSION: Whole-body muscle imaging provides clinically relevant information regarding muscle involvement in GSDIII. A severity score may contribute to improved patient management. Muscle Nerve, 2019.


Subject(s)
Glycogen Storage Disease Type III/diagnostic imaging , Muscle, Skeletal/diagnostic imaging , Adolescent , Adult , Female , Glycogen Storage Disease Type III/physiopathology , Humans , Magnetic Resonance Imaging , Male , Middle Aged , Muscle, Skeletal/physiopathology , Severity of Illness Index , Vital Capacity , Walk Test , Whole Body Imaging , Young Adult
3.
J Pediatr Endocrinol Metab ; 31(9): 979-986, 2018 Sep 25.
Article in English | MEDLINE | ID: mdl-30110253

ABSTRACT

Background Glycogen storage disease type III (GSDIII), due to a deficiency of glycogen debrancher enzyme (GDE), is particularly frequent in Tunisia. Phenotypic particularities of Tunisian patients remain unknown. Our aim was to study complications of GSDIII in a Tunisian population and to explore factors interfering with its course. Methods A retrospective longitudinal study was conducted over 30 years (1986-2016) in the referral metabolic center in Tunisia. Results Fifty GSDIII patients (26 boys), followed for an average 6.75 years, were enrolled. At the last evaluation, the median age was 9.87 years and 24% of patients reached adulthood. Short stature persisted in eight patients and obesity in 19 patients. Lower frequency of hypertriglyceridemia (HTG) was associated with older patients (p<0.0001), higher protein diet (p=0.068) and lower caloric intake (p=0.025). Hepatic complications were rare. Cardiac involvement (CI) was frequent (91%) and occurred early at a median age of 2.6 years. Severe cardiomyopathy (50%) was related to lower doses of uncooked cornstarch (p=0.02). Neuromuscular involvement (NMI) was constant, leading to a functional discomfort in 64% of cases and was disabling in 34% of cases. Severe forms were related to lower caloric (p=0.005) and protein intake (p<0.015). Conclusions A low caloric, protein and uncooked cornstarch intake is associated with a more severe outcome in GSDIII Tunisian patients. Neuromuscular and CIs were particularly precocious and severe, even in childhood. Genetic and epigenetic factors deserve to be explored.


Subject(s)
Diet , Glycogen Storage Disease Type III/physiopathology , Starch , Child , Female , Humans , Longitudinal Studies , Male , Prognosis , Retrospective Studies , Tunisia
4.
Biochim Biophys Acta Mol Basis Dis ; 1864(10): 3407-3417, 2018 10.
Article in English | MEDLINE | ID: mdl-30076962

ABSTRACT

Glycogen disease type III (GSDIII), a rare incurable autosomal recessive disorder due to glycogen debranching enzyme deficiency, presents with liver, heart and skeletal muscle impairment, hepatomegaly and ketotic hypoglycemia. Muscle weakness usually worsens to fixed myopathy and cardiac involvement may present in about half of the patients during disease. Management relies on careful follow-up of symptoms and diet. No common agreement was reached on sugar restriction and treatment in adulthood. We administered two dietary regimens differing in their protein and carbohydrate content, high-protein (HPD) and high-protein/glucose-free (GFD), to our mouse model of GSDIII, starting at one month of age. Mice were monitored, either by histological, biochemical and molecular analysis and motor functional tests, until 10 months of age. GFD ameliorated muscle performance up to 10 months of age, while HPD showed little improvement only in young mice. In GFD mice, a decreased muscle glycogen content and fiber vacuolization was observed, even in aged animals indicating a protective role of proteins against skeletal muscle degeneration, at least in some districts. Hepatomegaly was reduced by about 20%. Moreover, the long-term administration of GFD did not worsen serum parameters even after eight months of high-protein diet. A decreased phosphofructokinase and pyruvate kinase activities and an increased expression of Krebs cycle and gluconeogenesis genes were seen in the liver of GFD fed mice. Our data show that the concurrent use of proteins and a strictly controlled glucose supply could reduce muscle wasting, and indicate a better metabolic control in mice with a glucose-free/high-protein diet.


Subject(s)
Diet, High-Protein/methods , Glycogen Storage Disease Type III/diet therapy , Hepatomegaly/diet therapy , Muscle, Skeletal/physiopathology , Animals , Citric Acid Cycle , Diet, High-Protein Low-Carbohydrate/methods , Disease Models, Animal , Female , Glycogen Storage Disease Type III/metabolism , Glycogen Storage Disease Type III/physiopathology , Hepatomegaly/metabolism , Male , Mice , Mice, Knockout , Muscle, Skeletal/drug effects , Phosphofructokinases/metabolism , Physical Conditioning, Animal , Pyruvate Kinase/metabolism , Treatment Outcome
5.
J Clin Neuromuscul Dis ; 19(4): 203-210, 2018 Jun.
Article in English | MEDLINE | ID: mdl-29794575

ABSTRACT

OBJECTIVES: Glycogen storage disease type 3 (GSD-III) is a rare inherited metabolic disorder caused by glycogen debranching enzyme deficiency. Various pathogenic mutations of the AGL gene lead to abnormal accumulation of glycogen in liver, skeletal, and cardiac muscles. Here, we report distinct clinical and genetic data of Iranian patients with GSD-III. METHODS: Clinical and laboratory data of 5 patients with GSD-III were recorded. Genetic investigation was performed to identify the causative mutations. RESULTS: Three patients had typical liver involvement in childhood and one was diagnosed 2 years after liver transplantation for cirrhosis of unknown etiology. Four patients had vacuolar myopathy with glycogen excess in muscle biopsy. All patients had novel homozygous mutations of the AGL gene namely c.378T>A, c.3295T>C, c.3777G>A, c.2002-2A>G, and c.1183C>T. CONCLUSIONS: This is the first comprehensive report of patients with GSD-III in Iran with 2 uncommon clinical presentations and 5 novel mutations in the AGL gene.


Subject(s)
Glycogen Storage Disease Type III , Glycogen/genetics , Mutation/genetics , Adolescent , Adult , Female , Glycogen/metabolism , Glycogen Debranching Enzyme System/genetics , Glycogen Storage Disease Type III/genetics , Glycogen Storage Disease Type III/physiopathology , Glycogen Storage Disease Type III/surgery , Glycogen Storage Disease Type III/therapy , Humans , Iran/epidemiology , Liver Transplantation/methods , Male , Middle Aged , Muscle, Skeletal/physiopathology , Young Adult
6.
Ter Arkh ; 89(8): 88-94, 2017.
Article in Russian | MEDLINE | ID: mdl-28914857

ABSTRACT

Glycogen storage disease (GSD) is an inherited metabolic disorder characterized by early childhood lipid metabolic disturbances with potentially proatherogenic effects. The review outlines the characteristics of impaired lipid composition and other changes in the cardiovascular system in GSD types I and III. It analyzes the factors enabling and inhibiting the development of atherosclerosis in patients with GSD. The review describes the paradox of vascular resistance to the development of early atherosclerosis despite the proatherogenic composition of lipids in the patients of this group.


Subject(s)
Cardiovascular System , Glycogen Storage Disease Type III , Glycogen Storage Disease Type I , Lipid Metabolism , Atherosclerosis/etiology , Atherosclerosis/metabolism , Cardiovascular System/metabolism , Cardiovascular System/physiopathology , Glycogen Storage Disease Type I/complications , Glycogen Storage Disease Type I/metabolism , Glycogen Storage Disease Type I/physiopathology , Glycogen Storage Disease Type III/complications , Glycogen Storage Disease Type III/metabolism , Glycogen Storage Disease Type III/physiopathology , Humans , Vascular Resistance
7.
Mol Genet Metab ; 122(3): 108-116, 2017 11.
Article in English | MEDLINE | ID: mdl-28888851

ABSTRACT

Glycogen storage disease type III (GSDIII) is an autosomal recessive disorder caused by mutations in the AGL gene coding for the glycogen debranching enzyme. Current therapy is based on dietary adaptations but new preclinical therapies are emerging. The identification of outcome measures which are sensitive to disease progression becomes critical to assess the efficacy of new treatments in upcoming clinical trials. In order to prepare future longitudinal studies or therapeutic trials with large cohorts, information about disease progression is required. In this study we present preliminary longitudinal data of Motor Function Measure (MFM), timed tests, Purdue pegboard test, and handgrip strength collected over 5 to 9years of follow-up in 13 patients with GSDIII aged between 13 and 56years old. Follow-up for nine of the 13 patients was up to 9years. Similarly to our previous cross-sectional retrospective study, handgrip strength significantly decreased with age in patients older than 37years. MFM scores started to decline after the age of 35. The Purdue pegboard score also significantly reduced with increasing age (from 13years of age) but with large inter-visit variations. The time to stand up from a chair or to climb 4 stairs increased dramatically in some but not all patients older than 30years old. In conclusion, this preliminary longitudinal study suggests that MFM and handgrip strength are the most sensitive muscle function outcome measures in GSDIII patients from the end of their third decade. Sensitive muscle outcome measures remain to be identified in younger GSDIII patients but is challenging as muscle symptoms remain discrete and often present as accumulated fatigue.


Subject(s)
Glycogen Storage Disease Type III/complications , Glycogen Storage Disease Type III/physiopathology , Muscular Diseases/etiology , Adolescent , Adult , Cross-Sectional Studies , Female , Glycogen Storage Disease Type III/genetics , Hand Strength , Humans , Longitudinal Studies , Male , Middle Aged , Muscular Diseases/complications , Muscular Diseases/physiopathology , Outcome and Process Assessment, Health Care , Retrospective Studies , Time Factors , Young Adult
8.
Neuromuscul Disord ; 26(9): 584-92, 2016 09.
Article in English | MEDLINE | ID: mdl-27460348

ABSTRACT

Glycogen storage disease type III is an inherited metabolic disorder characterized by liver and muscle impairment. This study aimed to identify promising muscle function measures for future studies on natural disease progression and therapeutic trials. The age-effect on the manual muscle testing (MMT), the hand-held dynamometry (HHD), the motor function measure (MFM) and the Purdue pegboard test was evaluated by regression analysis in a cross-sectional retrospective single site study. In patients aged between 13 and 56 years old, the Purdue pegboard test and dynamometry of key pinch and knee extension strength were age-sensitive with annual losses of 1.49, 1.10 and 0.70% of the predicted values (%pred), respectively. The MFM score and handgrip strength were also age-sensitive but only in patients older than 29 and 37 years old with annual losses of 1.42 and 1.84%pred, respectively. Muscle strength assessed by MMT and elbow extension measured by HHD demonstrated an annual loss of less than 0.50%pred and are thus unlikely to be promising outcome measures for future clinical trials. In conclusion, our results identified age-sensitive outcomes from retrospective data and may serve for future longitudinal studies in which an estimation of the minimal number of subjects is provided.


Subject(s)
Glycogen Storage Disease Type III/physiopathology , Muscle, Skeletal/physiopathology , Adolescent , Adult , Aging/physiology , Arm/physiopathology , Cross-Sectional Studies , Female , Glycogen Storage Disease Type III/genetics , Hand Strength/physiology , Humans , Male , Middle Aged , Muscle Strength Dynamometer , Muscle Weakness/etiology , Muscle Weakness/physiopathology , Retrospective Studies , Young Adult
9.
Bone ; 86: 79-85, 2016 May.
Article in English | MEDLINE | ID: mdl-26924264

ABSTRACT

INTRODUCTION: Glycogen storage disease type III (GSDIII) is an inborn error of carbohydrate metabolism caused by deficient activity of glycogen debranching enzyme (GDE). It is characterized by liver, cardiac muscle and skeletal muscle involvement. The presence of systemic complications such as growth retardation, ovarian polycystosis, diabetes mellitus and osteopenia/osteoporosis has been reported. The pathogenesis of osteopenia/osteoporosis is still unclear. OBJECTIVES: The aim of the current study was to evaluate the bone mineral density (BMD) in GSDIII patients and the role of metabolic and endocrine factors and physical activity on bone status. METHODS: Nine GSDIII patients were enrolled (age 2-20years) and compared to eighteen age and sex matched controls. BMD was evaluated by Dual-emission-X-ray absorptiometry (DXA) and Quantitative ultrasound (QUS). Clinical and biochemical parameters of endocrine system function and bone metabolism were analyzed. Serum levels of the metabolic control markers were evaluated. Physical activity was evaluated by administering the International Physical Activity Questionnaire (IPAQ). RESULTS: GSDIII patients showed reduced BMD detected at both DXA and QUS, decreased serum levels of IGF-1, free IGF-1, insulin, calcitonin, osteocalcin (OC) and increased serum levels of C-terminal cross-linking telopeptide of type I collagen (CTX). IGF-1 serum levels inversely correlated with AST and ALT serum levels. DXA Z-score inversely correlated with cholesterol and triglycerides serum levels and directly correlated with IGF-1/IGFBP3 molar ratio. No difference in physical activity was observed between GSDIII patients and controls. DISCUSSION: Our data confirm the presence of reduced BMD in GSDIII. On the basis of the results, we hypothesized that metabolic imbalance could be the key factor leading to osteopenia, acting through different mechanisms: chronic hyperlipidemia, reduced IGF-1, Insulin and OC serum levels. Thus, the mechanism of osteopenia/osteoporosis in GSDIII is probably multifactorial and we speculate on the factors involved in its pathogenesis.


Subject(s)
Bone Density , Bone and Bones/metabolism , Glycogen Storage Disease Type III/metabolism , Glycogen Storage Disease Type III/physiopathology , Homeostasis , Absorptiometry, Photon , Adolescent , Biomarkers/blood , Calcitonin/blood , Case-Control Studies , Child , Child, Preschool , Cholesterol/blood , Exercise , Female , Glycogen Storage Disease Type III/blood , Hormones/blood , Humans , Male
10.
Ultrasound Med Biol ; 42(1): 133-42, 2016 Jan.
Article in English | MEDLINE | ID: mdl-26437929

ABSTRACT

In glycogen storage diseases (GSDs), improved longevity has resulted in the need for neuromuscular surveillance. In 12 children and 14 adults with the "hepatic" (GSD-I) and "myopathic" (GSD-III) phenotypes, we cross-sectionally assessed muscle ultrasound density (MUD) and muscle force. Children with both "hepatic" and "myopathic" GSD phenotypes had elevated MUD values (MUD Z-scores: GSD-I > 2.5 SD vs. GSD-III > 1 SD, p < 0.05) and muscle weakness (GSD-I muscle force; p < 0.05) of myopathic distribution. In "hepatic" GSD-I adults, MUD stabilized (GSD-I adults vs. GSD-I children, not significant), concurring with moderate muscle weakness (GSD-I adults vs. healthy matched pairs, p < 0.05). In "myopathic" GSD-III adults, MUD increased with age (MUD-GSD III vs. age: r = 0.71-0.83, GSD-III adults > GSD-III children, p < 0.05), concurring with pronounced muscle weakness (GSD-III adults vs. GSD-I adults, p < 0.05) of myopathic distribution. Children with "hepatic" and "myopathic" GSD phenotypes were both found to have myopathy. Myopathy stabilizes in "hepatic" GSD-I adults, whereas it progresses in "myopathic" GSD-III adults. Muscle ultrasonography provides an excellent, non-invasive tool for neuromuscular surveillance per GSD phenotype.


Subject(s)
Glycogen Storage Disease Type III/physiopathology , Glycogen Storage Disease Type I/physiopathology , Muscle, Skeletal/diagnostic imaging , Muscle, Skeletal/physiopathology , Adult , Child , Child, Preschool , Cross-Sectional Studies , Female , Glycogen Storage Disease Type I/diagnostic imaging , Glycogen Storage Disease Type III/diagnostic imaging , Humans , Male , Muscle Weakness/diagnostic imaging , Muscle Weakness/physiopathology , Ultrasonography
11.
Curr Opin Clin Nutr Metab Care ; 18(4): 415-21, 2015 Jul.
Article in English | MEDLINE | ID: mdl-26001652

ABSTRACT

PURPOSE OF REVIEW: Glycogen storage disorders (GSDs) are inborn errors of metabolism with abnormal storage or utilization of glycogen. The present review focuses on recent advances in hepatic GSD types I, III and VI/IX, with emphasis on clinical aspects and treatment. RECENT FINDINGS: Evidence accumulates that poor metabolic control is a risk factor for the development of long-term complications, such as liver adenomas, low bone density/osteoporosis, and kidney disease in GSD I. However, mechanisms leading to these complications remain poorly understood and are being investigated. Molecular causes underlying neutropenia and neutrophil dysfunction in GSD I have been elucidated. Case series provide new insights into the natural course and outcome of GSD types VI and IX. For GSD III, a high protein/fat diet has been reported to improve (cardio)myopathy, but the beneficial effect of this dietary concept on muscle and liver disease manifestations needs to be further established in prospective studies. SUMMARY: Although further knowledge has been gained regarding pathophysiology, disease course, treatment, and complications of hepatic GSDs, more controlled prospective studies are needed to assess effects of different dietary and medical treatment options on long-term outcome and quality of life.


Subject(s)
Glycogen Storage Disease Type III/physiopathology , Glycogen Storage Disease Type I/physiopathology , Glycogen Storage Disease Type VI/physiopathology , Liver/physiopathology , Animals , Cardiomyopathies/complications , Cardiomyopathies/diet therapy , Cardiomyopathies/physiopathology , Diet, Carbohydrate-Restricted , Diet, High-Fat , Dietary Carbohydrates/administration & dosage , Dietary Fats/administration & dosage , Dietary Proteins/administration & dosage , Disease Models, Animal , Glycogen/metabolism , Glycogen Storage Disease Type I/complications , Glycogen Storage Disease Type I/diagnosis , Glycogen Storage Disease Type I/diet therapy , Glycogen Storage Disease Type III/complications , Glycogen Storage Disease Type III/diagnosis , Glycogen Storage Disease Type III/diet therapy , Glycogen Storage Disease Type VI/complications , Glycogen Storage Disease Type VI/diagnosis , Glycogen Storage Disease Type VI/diet therapy , Humans , Liver Cirrhosis/complications , Liver Cirrhosis/diet therapy , Liver Cirrhosis/physiopathology
12.
Neurology ; 84(17): 1767-71, 2015 Apr 28.
Article in English | MEDLINE | ID: mdl-25832663

ABSTRACT

OBJECTIVE: Glycogen storage disease type IIIa (GSDIIIa) is classically regarded as a glycogenosis with fixed weakness, but we hypothesized that exercise intolerance in GSDIIIa is related to muscle energy failure and that oral fructose ingestion could improve exercise tolerance in this metabolic myopathy. METHODS: We challenged metabolism with cycle-ergometer exercise and measured substrate turnover and oxidation rates using stable isotope methodology and indirect calorimetry in 3 patients and 6 age-matched controls on 1 day, and examined the effect of fructose ingestion on exercise tolerance in the patients on another day. RESULTS: Total fatty acid oxidation rates during exercise were higher in patients than controls, 32.1 (SE 1.2) vs 20.7 (SE 0.5; range 15.8-29.3) µmol/kg/min (p = 0.048), and oxidation of carbohydrates was lower in patients, 1.0 (SE 5.4) vs 38.4 (SE 8.0; range 23.0-77.1) µmol/kg/min (p = 0.024). Fructose ingestion improved exercise tolerance in the patients. CONCLUSION: Similar to patients with McArdle disease, in whom muscle glycogenolysis is also impaired, GSDIIIa is associated with a reduced skeletal muscle oxidation of carbohydrates and a compensatory increase in fatty acid oxidation, and fructose ingestion improves exercise tolerance. Our results indicate that GSDIIIa should not only be viewed as a glycogenosis with fixed skeletal muscle weakness, but should also be considered among the glycogenoses presenting with exercise-related dynamic symptoms caused by muscular energy deficiency. CLASSIFICATION OF EVIDENCE: This study provides Class IV evidence that ingestion of fructose improves exercise tolerance in patients with GSDIIIa.


Subject(s)
Energy Metabolism/physiology , Exercise , Fructose/pharmacology , Glycogen Storage Disease Type III/metabolism , Muscle Weakness/metabolism , Muscle, Skeletal/metabolism , Adolescent , Adult , Fructose/administration & dosage , Glycogen Storage Disease Type III/diet therapy , Glycogen Storage Disease Type III/physiopathology , Humans , Muscle Weakness/diet therapy , Muscle, Skeletal/physiopathology , Young Adult
13.
J Pediatr Endocrinol Metab ; 28(1-2): 195-200, 2015 Jan.
Article in English | MEDLINE | ID: mdl-25153581

ABSTRACT

AIM: To determine the individual fasting tolerance for patients with glycogen storage disease type III (GSD III) and to assess their linear growth velocity after tailoring of dose intervals of oral uncooked cornstarch. PATIENTS AND METHODS: A prospective cohort study included 32 patients with GSD III aged 6 months-11.5 years (median: 3.3 years). The fasting tolerance of each patient was determined as the time interval between starch administration until the drop in blood glucose level was below 60 mg/dL. RESULTS: Some 27 patients (84.4%) developed hypoglycemia. The intervals between oral cornstarch administration were tailored for each child according to his/her individual fasting tolerance. After a 6-month follow up there was a significant reduction in seizure attacks (p<0.01) and liver size (p<0.01), but there was no statistically significant difference in liver transaminase and serum lactate levels. There was a significant improvement in height (p<0.01) and linear growth velocity (p<0.05) of these patients after at least a 12-month follow up. CONCLUSION: Adjusting the intervals between the cornstarch doses for each patient with GSD III, according to individual fasting tolerance test was very beneficial and resulted in improvement of the linear growth velocity and reduction in the frequency of hypoglycemic seizures as well as the size of the liver. Individual scheduling of cornstarch doses prevents complications in those who develop hypoglycemia at short intervals; it also allows some relaxation in schedule for those who can tolerate longer fasting hours to improve their appetite and prolong their uninterrupted sleep hours.


Subject(s)
Body Height/drug effects , Glycogen Storage Disease Type III/blood , Glycogen Storage Disease Type III/diet therapy , Glycogen Storage Disease Type III/diagnosis , Starch/administration & dosage , Blood Glucose/drug effects , Blood Glucose/metabolism , Child , Child Development/drug effects , Child, Preschool , Fasting/blood , Female , Follow-Up Studies , Glycogen Storage Disease Type III/physiopathology , Humans , Hypoglycemia/blood , Hypoglycemia/epidemiology , Infant , Male , Starch/pharmacology
14.
Mol Genet Metab ; 111(4): 467-76, 2014 Apr.
Article in English | MEDLINE | ID: mdl-24613482

ABSTRACT

Glycogen storage disease type IIIa (GSD IIIa) is caused by a deficiency of the glycogen debranching enzyme (GDE), which is encoded by the Agl gene. GDE deficiency leads to the pathogenic accumulation of phosphorylase limit dextrin (PLD), an abnormal glycogen, in the liver, heart, and skeletal muscle. To further investigate the pathological mechanisms behind this disease and develop novel therapies to treat this disease, we generated a GDE-deficient mouse model by removing exons after exon 5 in the Agl gene. GDE reduction was confirmed by western blot and enzymatic activity assay. Histology revealed massive glycogen accumulation in the liver, muscle, and heart of the homozygous affected mice. Interestingly, we did not find any differences in the general appearance, growth rate, and life span between the wild-type, heterozygous, and homozygous affected mice with ad libitum feeding, except reduced motor activity after 50 weeks of age, and muscle weakness in both the forelimb and hind legs of homozygous affected mice by using the grip strength test at 62 weeks of age. However, repeated fasting resulted in decreased survival of the knockout mice. Hepatomegaly and progressive liver fibrosis were also found in the homozygous affected mice. Blood chemistry revealed that alanine transaminase (ALT), aspartate transaminase (AST) and alkaline phosphatase (ALP) activities were significantly higher in the homozygous affected mice than in both wild-type and heterozygous mice and the activity of these enzymes further increased with fasting. Creatine phosphokinase (CPK) activity was normal in young and adult homozygous affected mice. However, the activity was significantly elevated after fasting. Hypoglycemia appeared only at a young age (3 weeks) and hyperlipidemia was not observed in our model. In conclusion, with the exception of normal lipidemia, these mice recapitulate human GSD IIIa; moreover, we found that repeated fasting was detrimental to these mice. This mouse model will be useful for future investigation regarding the pathophysiology and treatment strategy of human GSD III.


Subject(s)
Disease Models, Animal , Glycogen Storage Disease Type III/pathology , Animals , Fasting/blood , Female , Glycogen/metabolism , Glycogen Debranching Enzyme System/deficiency , Glycogen Debranching Enzyme System/genetics , Glycogen Storage Disease Type III/blood , Glycogen Storage Disease Type III/enzymology , Glycogen Storage Disease Type III/physiopathology , Humans , Immunoblotting , Liver/pathology , Male , Mice , Mice, Knockout , Muscle Strength , Organ Specificity
15.
Vestn Ross Akad Med Nauk ; (7-8): 78-84, 2014.
Article in Russian | MEDLINE | ID: mdl-25563007

ABSTRACT

AIM: The purpose of the study was to assess mitochondrial dysfunction severity in patients with hepatic forms of glycogen storage disease (GSD). PATIENTS AND METHODS: We examined 53 children with GSD in the dynamics. Distribution of children by disease types was: 1st group--children with GSD type I, 2nd group--children with GSD type III, 3rd group--children with GSD type VI and IX; comparison group consisted of 34 healthy children. Intracellular dehydrogenases activity: succinate dehydrogenase (SDH), glycerol-3-phosphate-dehydrogenase (GPDH). nicotinamideadenin-H-dehydrogenase (NADH-D) and lactatdehydrogenase (LDH) was measured using the quantitative cytochemical method in the peripheral lymphocytes. RESULTS: It was revealed decrease of SDH- (p < 0.001) and GPDH-activities (p < 0.001), along with increase of the NADH-D activity (p < 0.05) in all patients with GSD, (SDH/ NADH-D) index was decreased (p < 0.001). LDH activity was increased in groups 1 (p < 0.05) and 3 (p < 0.01), compared with comparison group. The most pronounced intracellular enzymes activity deviations were observed in children with GSD type I, that correspond to more severe clinical form of GSD. It was found strong correlation between intracellular enzymes activity and both hepatomegaly level (R = 0.867) and metabolic acidosis severity (R = 0.987). CONCLUSION: Our investigation revealed features of mitochondrial dysfunction in children with GSD, depending on the GSD type. Activities of lymphocytes enzymes correlates with the main disease severity parameters and can be used as an additional diagnostic criteria in children with hepatic form of GSD.


Subject(s)
Glycogen Storage Disease Type III , Glycogen Storage Disease Type I , Glycogen Storage Disease Type VI , Liver , Lymphocytes/metabolism , Mitochondria/metabolism , Carbohydrate Metabolism , Child , Cytological Techniques/methods , Female , Glycogen Storage Disease Type I/diagnosis , Glycogen Storage Disease Type I/metabolism , Glycogen Storage Disease Type I/physiopathology , Glycogen Storage Disease Type III/diagnosis , Glycogen Storage Disease Type III/metabolism , Glycogen Storage Disease Type III/physiopathology , Glycogen Storage Disease Type VI/diagnosis , Glycogen Storage Disease Type VI/metabolism , Glycogen Storage Disease Type VI/physiopathology , Humans , Liver/metabolism , Liver/pathology , Liver/physiopathology , Male , Oxidoreductases/analysis , Oxidoreductases/classification , Oxidoreductases/metabolism , Severity of Illness Index , Statistics as Topic
16.
Clin EEG Neurosci ; 45(3): 201-4, 2014 Jul.
Article in English | MEDLINE | ID: mdl-24357677

ABSTRACT

Glycogen storage diseases are rare genetic disorders, mostly autosomal recessively inherited. Abnormal accumulation is because of the lack of one of the enzymes involved in glycogen metabolism. Neurological manifestation of the diseases involves muscle weakness and hypoglycemia-induced seizures. In this article, we present a history of twin sisters with unusual coincidence of glycogenosis type IIIb and epilepsy. Hypoglycemic background of seizures and organic changes of the central nervous system were excluded. Since the introduction of antiepileptic treatment, the patients have been seizure-free; however, paroxysmal electroencephalographic (EEG) changes have persisted. A high-protein and low-carbohydrate diet has protected them against hypoglycemia.


Subject(s)
Brain Mapping/methods , Diseases in Twins/genetics , Diseases in Twins/physiopathology , Electroencephalography/methods , Epilepsy/genetics , Epilepsy/physiopathology , Glycogen Storage Disease Type III/genetics , Glycogen Storage Disease Type III/physiopathology , Signal Processing, Computer-Assisted , Spasms, Infantile/genetics , Spasms, Infantile/physiopathology , Anticonvulsants/therapeutic use , Cerebral Cortex/drug effects , Cerebral Cortex/physiopathology , Child, Preschool , Combined Modality Therapy , Diet, Carbohydrate-Restricted , Dietary Proteins/administration & dosage , Diseases in Twins/diagnosis , Diseases in Twins/therapy , Epilepsy/diagnosis , Epilepsy/therapy , Female , Follow-Up Studies , Genetic Carrier Screening , Glycogen Storage Disease Type III/diagnosis , Humans , Infant , Infant, Newborn , Poland , Spasms, Infantile/diagnosis , Spasms, Infantile/therapy
17.
Mol Genet Metab ; 109(1): 14-20, 2013 May.
Article in English | MEDLINE | ID: mdl-23507172

ABSTRACT

Myopathic symptoms in Glycogen Storage Disease Type IIIa (GSD IIIa) are generally ascribed to the muscle wasting that these patients suffer in adult life, but an inability to debranch glycogen likely also has an impact on muscle energy metabolism. We hypothesized that patients with GSD IIIa can experience exercise intolerance due to insufficient carbohydrate oxidation in skeletal muscle. Six patients aged 17-36-years were studied. We determined VO 2peak (peak oxygen consumption), the response to forearm exercise, and the metabolic and cardiovascular responses to cycle exercise at 70% of VO 2peak with either a saline or a glucose infusion. VO 2peak was below normal. Glucose improved the work capacity by lowering the heart rate, and increasing the peak work rate by 30% (108 W with glucose vs. 83 W with placebo, p=0.018). The block in muscle glycogenolytic capacity, combined with the liver involvement caused exercise intolerance with dynamic skeletal muscle symptoms (excessive fatigue and muscle pain), and hypoglycemia in 4 subjects. In this study we combined anaerobic and aerobic exercise to systematically study skeletal muscle metabolism and exercise tolerance in patients with GSD IIIa. Exercise capacity was significantly reduced, and our results indicate that this was due to a block in muscle glycogenolytic capacity. Our findings suggest that the general classification of GSD III as a glycogenosis characterized by fixed symptoms related to muscle wasting should be modified to include dynamic exercise-related symptoms of muscle fatigue. A proportion of the skeletal muscle symptoms in GSD IIIa, i.e. weakness and fatigue, may be related to insufficient energy production in muscle.


Subject(s)
Energy Metabolism , Fatigue/metabolism , Glycogen Storage Disease Type III/physiopathology , Muscle Weakness/metabolism , Adolescent , Adult , Body Mass Index , Carbohydrate Metabolism , Exercise , Fatigue/physiopathology , Female , Glycogen Storage Disease Type III/metabolism , Humans , Male , Muscle Weakness/physiopathology , Muscle, Skeletal/metabolism , Muscle, Skeletal/physiopathology
SELECTION OF CITATIONS
SEARCH DETAIL
...